Safety, Pharmacokinetics, and Pharmacodynamics of the Autotaxin Inhibitor GLPG1690 in Healthy Subjects: Phase 1 Randomized Trials.

In a recent phase 2a study in 23 patients with IPF (FLORA study), GLPG1690 600 mg once daily reduced plasma LPA C18:2 levels by at least 50% over 12 weeks; in the same treatment period, FVC showed a trend for a decline in the placebo group (mean change from baseline in week 12, ‐70 mL [95%CI, ‐208 to 68]) but remained similar to or greater than baseline values in the GLPG1690 600‐mg once‐daily group (mean change from baseline in week 12, +25 mL [95%CI, ‐75 to 124]). 21 This provides support for the concept of targeting the autotaxin‐LPA axis via inhibition of autotaxin to ameliorate IPF.

also in 53,322 other papers